WestEnd Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.4K | Hold |
96
| – | – | ﹤0.01% | 76 |
|
|
2025
Q4 | $11.8K | Buy |
96
+59
| +159% | +$7.17K | ﹤0.01% | 82 |
|
|
2025
Q3 | $4.11K | Sell |
37
-16
| -30% | -$1.82K | ﹤0.01% | 107 |
|
|
2025
Q2 | $5.88K | Buy |
53
+6
| +13% | +$639 | ﹤0.01% | 100 |
|
|
2025
Q1 | $5.27K | Buy |
47
+31
| +194% | +$3.2K | ﹤0.01% | 95 |
|
|
2024
Q4 | $1.48K | Buy |
16
+2
| +14% | +$180 | ﹤0.01% | 112 |
|
|
2024
Q3 | $1.17K | Sell |
14
-2
| -13% | -$153 | ﹤0.01% | 115 |
|
|
2024
Q2 | $1.1K | Sell |
16
-4
| -20% | -$267 | ﹤0.01% | 116 |
|
|
2024
Q1 | $1.47K | Buy |
20
+1
| +5% | +$77 | ﹤0.01% | 99 |
|
|
2023
Q4 | $1.54K | Buy |
19
+2
| +12% | +$156 | ﹤0.01% | 101 |
|
|
2023
Q3 | $1.27K | Buy |
+17
| New | +$1.31K | ﹤0.01% | 99 |
|
|
2023
Q1 | – | Sell |
-15
| Closed | -$1.24K | – | 91 |
|
|
2022
Q4 | $1.29K | Sell |
15
-1
| -6% | -$79 | ﹤0.01% | 90 |
|
|
2022
Q3 | $1K | Buy |
16
+1
| +7% | +$63 | ﹤0.01% | 110 |
|
|
2022
Q2 | $927 | Buy |
+15
| New | +$929 | ﹤0.01% | 111 |
|
|
2022
Q1 | – | Sell |
-10
| Closed | -$639 | – | 125 |
|
|
2021
Q4 | $726 | Buy |
+10
| New | +$689 | ﹤0.01% | 125 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 124 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 120 |
|
|
2020
Q1 | – | Sell |
-454,472
| Closed | -$29.5M | – | 63 |
|
|
2019
Q4 | $29.5M | Sell |
454,472
-27,531
| -6% | -$1.79M | 2.23% | 26 |
|
|
2019
Q3 | $30.5M | Sell |
482,003
-24,245
| -5% | -$1.58M | 2.51% | 20 |
|
|
2019
Q2 | $34.2M | Sell |
506,248
-29,445
| -5% | -$1.94M | 2.97% | 11 |
|
|
2019
Q1 | $34.8M | Buy |
535,693
+89,886
| +20% | +$5.97M | 3.27% | 20 |
|
|
2018
Q4 | $27.9M | Sell |
445,807
-74,155
| -14% | -$5.18M | 2.99% | 19 |
|
|
2018
Q3 | $40.1M | Sell |
519,962
-12,890
| -2% | -$973K | 3.84% | 11 |
|
|
2018
Q2 | $37.7M | Sell |
532,852
-16,906
| -3% | -$1.19M | 3.92% | 11 |
|
|
2018
Q1 | $41.4M | Buy |
549,758
+3,657
| +0.7% | +$291K | 3.9% | 16 |
|
|
2017
Q4 | $39.1M | Sell |
546,101
-155,362
| -22% | -$11.8M | 3.62% | 18 |
|
|
2017
Q3 | $56.8M | Sell |
701,463
-54,002
| -7% | -$4.13M | 4.99% | 2 |
|
|
2017
Q2 | $53.5M | Sell |
755,465
-60,253
| -7% | -$4.01M | 4.57% | 10 |
|
|
2017
Q1 | $55.4M | Buy |
815,718
+80,685
| +11% | +$5.67M | 4.63% | 15 |
|
|
2016
Q4 | $52.6M | Sell |
735,033
-128,783
| -15% | -$9.57M | 4.2% | 18 |
|
|
2016
Q3 | $68.3M | Sell |
863,816
-254,584
| -23% | -$20.7M | 4.9% | 10 |
|
|
2016
Q2 | $93.3M | Buy |
1,118,400
+35,826
| +3% | +$3.18M | 4.95% | 9 |
|
|
2016
Q1 | $99.4M | Buy |
1,082,574
+124,198
| +13% | +$11.2M | 4.82% | 17 |
|
|
2015
Q4 | $97M | Buy |
958,376
+20,361
| +2% | +$2.12M | 4.75% | 14 |
|
|
2015
Q3 | $92.1M | Sell |
938,015
-101,032
| -10% | -$11.2M | 4.66% | 14 |
|
|
2015
Q2 | $122M | Sell |
1,039,047
-55,239
| -5% | -$6.04M | 5.63% | 3 |
|
|
2015
Q1 | $107M | Buy |
1,094,286
+96,247
| +10% | +$9.77M | 4.83% | 17 |
|
|
2014
Q4 | $94.1M | Buy |
998,039
+84,641
| +9% | +$8.75M | 4.3% | 20 |
|
|
2014
Q3 | $97.2M | Sell |
913,398
-333,193
| -27% | -$32.6M | 4.91% | 14 |
|
|
2014
Q2 | $103M | Sell |
1,246,591
-32,710
| -3% | -$2.55M | 5.07% | 4 |
|
|
2014
Q1 | $90.7M | Buy |
1,279,301
+350,401
| +38% | +$27.5M | 4.43% | 19 |
|
|
2013
Q4 | $69.8M | Sell |
928,900
-437,523
| -32% | -$30.5M | 2.52% | 21 |
|
|
2013
Q3 | $85.9M | Sell |
1,366,423
-133,501
| -9% | -$7.98M | 2.81% | 20 |
|
|
2013
Q2 | $76.9M | Buy |
+1,499,924
| New | +$78.2M | 2.53% | 20 |
|
Other funds holding GILD
VCM
VPM
WestEnd Advisors's GILD Position: Q1 2026 in Review
WestEnd Advisors held its Gilead Sciences (GILD) position steady in Q1 2026 at 96 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #76.
WestEnd Advisors first reported a position in GILD in Q2 2013 and has held it in 42 quarters since. The position peaked at $122M in Q2 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- WestEnd Advisors held 96 shares of Gilead Sciences worth $13.4K as of Q1 2026.
- WestEnd Advisors left its Gilead Sciences share count unchanged in Q1 2026.
- Gilead Sciences made up ﹤0.01% of WestEnd Advisors's portfolio in Q1 2026, its #76 holding.
- WestEnd Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 42 quarters since.
- WestEnd Advisors's Gilead Sciences position peaked at $122M in Q2 2015.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on WestEnd Advisors's 13F filing for Q1 2026, filed 22 Apr 2026.